Arbutus Biopharma (ABUS) Non-Current Deffered Revenue (2017 - 2025)
Historic Non-Current Deffered Revenue for Arbutus Biopharma (ABUS) over the last 12 years, with Q1 2025 value amounting to $2.9 million.
- Arbutus Biopharma's Non-Current Deffered Revenue changed N/A to $2.9 million in Q1 2025 from the same period last year, while for Mar 2025 it was $2.9 million, marking a year-over-year change of. This contributed to the annual value of $2.9 million for FY2024, which is N/A changed from last year.
- Latest data reveals that Arbutus Biopharma reported Non-Current Deffered Revenue of $2.9 million as of Q1 2025.
- Arbutus Biopharma's 5-year Non-Current Deffered Revenue high stood at $15.6 million for Q1 2022, and its period low was $2.9 million during Q4 2024.
- In the last 4 years, Arbutus Biopharma's Non-Current Deffered Revenue had a median value of $6.0 million in 2022 and averaged $7.4 million.
- Data for Arbutus Biopharma's Non-Current Deffered Revenue shows a peak YoY increase of 7885.15% (in 2023) and a maximum YoY decrease of 7885.15% (in 2023) over the last 5 years.
- Quarter analysis of 4 years shows Arbutus Biopharma's Non-Current Deffered Revenue stood at $6.0 million in 2022, then plummeted by 45.06% to $3.3 million in 2023, then fell by 13.14% to $2.9 million in 2024, then changed by 0.0% to $2.9 million in 2025.
- Its Non-Current Deffered Revenue was $2.9 million in Q1 2025, compared to $2.9 million in Q4 2024 and $3.3 million in Q1 2023.